
Madrigal closes on EU approval of first MASH treatment
Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.
Newsletters and Deep Dive digital magazine
Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.
Grail is eyeing FDA approval of its Galleri cancer screening blood test after a second positive phase 3 trial.
The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.
Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.
Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Editor's Picks
Newsletters and Deep Dive
digital magazine